Facial Volume Loss, Hair Changes Among GLP-1 Dermatologic Concerns: Analysis

A new narrative review published in Clinics in Dermatology took a closer look at the cutaneous effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), including facial volume loss, hair changes, skin laxity, and potential benefits in inflammatory skin diseases.

Researchers from the Icahn School of Medicine at Mount Sinai evaluated the dermatologic implications of GLP-1RA use as these medications become increasingly common in the management of type 2 diabetes, obesity, and other metabolic conditions.

GLP-1 Medications: Skin Changes and Treatment Options

The review addressed six areas of dermatologic concern: facial volume loss and accelerated skin aging, changes in hair density, wound healing, striae distensae and body skin laxity, cutaneous adverse events, and emerging therapeutic applications in inflammatory skin disease. They also examined proposed mechanisms underlying these effects and available aesthetic management strategies, including biostimulatory fillers, energy-based devices, nutritional optimization, and pharmacologic interventions.

Although the review outlines potential approaches to managing GLP-1RA-associated skin changes, the authors emphasize that additional research is necessary to better characterize these effects and establish evidence-based treatment strategies.

"Prospective, large-scale clinical studies are needed to clarify mechanisms of GLP-1RA modulation in skin and to guide management of these AEs as next-generation agents enter clinical practice," the authors wrote.

Source

Hu BD, et al. Clin Dermatol. 2026. Doi:10.1016/j.clindermatol.2026.09.041

Article also posted at ModernAesthetics.com